Research statistics

Amycretin research: publications and trials

What has been published on Amycretin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Amycretin works or is safe. For what it is and what the studies found, see the Amycretin profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

16

Since 2025

Publications in 2026 so far

10

Through November 15, 2026

Human clinical research

31.3%

5 of 16 classified

Registered clinical trials

12

ClinicalTrials.gov

Randomized controlled trials

4

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

12.5%

1 animal · 0 in vitro · 1 computational

Records that only mention it

10

Not counted above

Status in the library: In clinical trials. Groups: Amylin analogues, GLP-1 receptor agonists.

What to keep in mind

  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.

Publications by year

Amycretin publications by year and evidence

2025, Human clinical research: 2 of 62025, Preclinical (animal, in vitro, computational): 2 of 62025, Reviews and meta-analyses: 1 of 62025, Other and not yet classified: 1 of 62026 (to date), Human clinical research: 3 of 102026 (to date), Reviews and meta-analyses: 6 of 102026 (to date), Other and not yet classified: 1 of 10Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified051020252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202522116
2026 (to date)306110

Study types

Review6
Randomized controlled trial4
Editorial, letter or other2
Animal study1
Other clinical trial1
Computational study1
Systematic review1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health12
Obesity and weight management11
Endocrinology6
Reproductive and sexual health1

Registered clinical trials

A registration is not a result.

Not yet recruiting: 6 · Recruiting: 6
Phase 1: 3 · Phase 3: 9

TrialStatusPhaseStartedResults
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNCT07668401 · 400 enrolledNot yet recruitingPhase 32027-01—
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT07931495 · 200 enrolledNot yet recruitingPhase 32026-11—
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothNCT07931547 · 450 enrolledNot yet recruitingPhase 32026-11—
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNCT07931573 · 1,200 enrolledNot yet recruitingPhase 32026-11—
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNCT07931599 · 1,060 enrolledNot yet recruitingPhase 32026-11—
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 8,500 enrolledNot yet recruitingPhase 32026-10—
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationNCT07868354 · 60 enrolledRecruitingPhase 12026-10—
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationNCT07855133 · 60 enrolledRecruitingPhase 12026-10—
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 · 650 enrolledRecruitingPhase 32026-09—
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityNCT07815067 · 320 enrolledRecruitingPhase 12026-09—
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271 · 950 enrolledRecruitingPhase 32026-08—
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 1,778 enrolledRecruitingPhase 32026-08—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

    Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times

    PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses

  2. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

    Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times

    PMID 42532080 · DOI 10.1016/s0140-6736(26)01248-1 · Human clinical research

  3. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

    Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times

    PMID 42532079 · DOI 10.1016/s0140-6736(26)01247-x · Human clinical research

  4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

    Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 45 times

    PMID 40550229 · DOI 10.1016/s0140-6736(25)01176-6 · Human clinical research

  5. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

    Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 76 times

    PMID 40550231 · DOI 10.1016/s0140-6736(25)01185-7 · Human clinical research

  6. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.

    Diabetes, obesity & metabolism · July 13, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42443140 · DOI 10.1111/dom.71096 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

    Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 76 times

    PMID 40550231 · DOI 10.1016/s0140-6736(25)01185-7 · Human clinical research

  2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

    Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 45 times

    PMID 40550229 · DOI 10.1016/s0140-6736(25)01176-6 · Human clinical research

  3. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

    Endocrine reviews · March 1, 2026 · Review · cited 37 times

    PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses

  4. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.

    EBioMedicine · July 23, 2025 · Animal study · cited 26 times · open access

    PMID 40706446 · DOI 10.1016/j.ebiom.2025.105862 · Animal studies

  5. Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.

    Vascular pharmacology · December 2, 2025 · Review · cited 7 times

    PMID 41344603 · DOI 10.1016/j.vph.2025.107563 · Reviews and meta-analyses

Latest publications

  1. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.

    JAMA · November 1, 2026 · Editorial, letter or other · cited 0 times

    PMID 42853576 · DOI 10.1001/jama.2026.20514 · Commentary and other

  2. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.

    Diabetes therapy : research, treatment and education of diabetes and related disorders · September 28, 2026 · Review · cited 0 times · open access

    PMID 42803913 · DOI 10.1007/s13300-026-01921-0 · Reviews and meta-analyses

  3. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

    Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times

    PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses

  4. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

    Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times

    PMID 42532080 · DOI 10.1016/s0140-6736(26)01248-1 · Human clinical research

  5. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

    Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times

    PMID 42532079 · DOI 10.1016/s0140-6736(26)01247-x · Human clinical research

  6. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.

    Diabetes, obesity & metabolism · July 13, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42443140 · DOI 10.1111/dom.71096 · Human clinical research

  7. Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.

    Endocrinology, diabetes & metabolism · May 1, 2026 · Review · cited 0 times · open access

    PMID 42175595 · DOI 10.1002/edm2.70247 · Reviews and meta-analyses

  8. Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.

    Metabolism: clinical and experimental · March 17, 2026 · Review · cited 2 times

    PMID 41850421 · DOI 10.1016/j.metabol.2026.156594 · Reviews and meta-analyses

  9. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

    Endocrine reviews · March 1, 2026 · Review · cited 37 times

    PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses

  10. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

    Peptides · February 24, 2026 · Review · cited 6 times · open access

    PMID 41747885 · DOI 10.1016/j.peptides.2026.171480 · Reviews and meta-analyses

Browse all 16 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Amycretin; NN9487; Zenagamtide

((TITLE_ABS:"Amycretin" OR CHEM:"Amycretin") OR (TITLE_ABS:"NN9487" OR CHEM:"NN9487" OR TITLE_ABS:"NN 9487" OR CHEM:"NN 9487") OR (TITLE_ABS:"Zenagamtide" OR CHEM:"Zenagamtide")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Amycretin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/amycretin